In the Claims

Claims 34-36 have been added in the application.

Claim 1 is amended as follows.

1. (currently amended) An oral drug delivery composition comprising a chromone wherein (1) not more than 10% of the chromone dissolves after two hours exposure of the composition to simulated gastric fluid and (2) at least 15 ~~80%~~ of the chromone dissolves within 10 ~~5~~ minutes of subsequent exposure of the composition to simulated intestinal fluid, said composition further comprising disintegrant at a ratio of at least 1.2:1 ~~1.4:1~~ (w:w) of disintegrant to chromone wherein said disintegrant is selected from the group consisting of microcrystalline cellulose, croscarmellose sodium, crosprovidone, sodium starch glycolate, and combinations thereof.

2. (original) A composition according to claim 1 wherein the composition is formulated as a tablet.

3. (original) A composition according to claim 2 wherein the tablet has an enteric coating.

4. (original) A composition according to claim 2 or 3 wherein the composition is still in the form of a tablet at the end of the exposure of the composition to gastric fluid.

5. (original) The composition according to any one of claims 2 to 4 wherein the tablet comprises between about 50mg and 200mg of chromone.

6. (previously cancelled).

7. (original) A composition according to claim 1 wherein the composition comprises substantially spherical pellets of up to 5 mm diameter comprising the chromone, each pellet having an enteric coating.

8. (previously amended) An oral drug delivery composition comprising a chromone wherein the composition further comprises disintegrant at a ratio of at least 1.5:1 (w:w) of disintegrant to chromone.

9. (previously amended) A composition according to claim 1 or claim 8 wherein the ratio of disintegrant to chromone is between about 1.5:1 and 2.5:1

10-15. (previously withdrawn)

16. (previously amended) A composition according to any one of claims 1, 8, or 9 wherein the disintegrant is microcrystalline cellulose.

17-29. (previously withdrawn)

30. (previously amended) A composition according to any one of the preceding claims further comprising an amphoteric surfactant or a surfactant having a hydrophile-lipophile balance (HLB) value of less than about 10.

31-32. (previously cancelled).

33. (previously added) A composition according to any one of the preceding claims wherein the chromone is sodium cromoglycate.

34. (newly added) An oral drug delivery composition comprising a chromone wherein (1) not more than 10% of the chromone dissolves after two hours exposure of the composition to simulated gastric fluid, and (2) at least about 80% of the chromone dissolves within about 5 minutes of subsequent exposure of the composition to simulated intestinal fluid, said composition further comprising microcrystalline cellulose at a ratio of at least 1.4:1 (w:w) of microcrystalline cellulose to chromone.

35. (newly added) An oral drug delivery composition comprising a chromone wherein (1) not more than 10% of the chromone dissolves after two hours exposure of the composition to simulated gastric fluid, and (2) at least about 27% of the chromone dissolves within about 10 minutes of subsequent exposure of the composition to simulated intestinal fluid, said composition further comprising disintegrant at a ratio of at least 1.2:1 (w:w) of disintegrant to chromone, wherein said disintegrant is selected from the group consisting of croscarmellose sodium, crosprovidone, sodium starch glycolate, and a blend

of croscarmellose sodium and microcrystalline cellulose at a ratio of about 1:9 (w:w) of croscarmellose sodium to microcrystalline cellulose.

36. (newly added) An oral drug delivery composition comprising a chromone wherein (1) not more than 10% of the chromone dissolves after two hours exposure of the composition to simulated gastric fluid, and (2) at least about 21% of the chromone dissolves within about 5 minutes of subsequent exposure of the composition to simulated intestinal fluid, said composition further comprising disintegrant at a ratio of at least 1.4:1 (w:w) of disintegrant to chromone, wherein said disintegrant is selected from the group consisting of super disintegrants in the form of a cross-linked cellulose, a cross-linked polymer, a cross-linked starch, and microcrystalline cellulose.